)
Annalisa Jenkins, MBBS, FRCP, is a biopharma thought leader with more than 25 years’ industry experience. She has extensive experience in building and financing biotech companies pursuing cures for challenging rare diseases. She has built and led teams advancing programmes from scientific research through clinical development, regulatory approval, and into health care systems globally. She is an advocate for diversity and inclusion, particularly for women in science.
Annalisa has served as President and Chief Executive of Dimension Therapeutics and other leadership roles have included senior positions at Merck Serono and at Bristol Myers-Squibb. Earlier in her career, Annalisa was a medical officer in the British Royal Navy.
She is a board member of several growing companies, including Oncimmune, AVROBIO, COMPASS Pathways, AOBiome, AgeX; a medical trustee for the British Heart Foundation; a committee member of the Science Board to the US Food and Drug Administration; advisory board member at FasterCures; and Chair of Court at the London School of Hygiene and Tropical Medicine.